Mode
Text Size
Log in / Sign up

Functional precision medicine approaches may complement current paradigms for non-metastatic colorectal cancer management.

Functional precision medicine approaches may complement current paradigms for non-metastatic colorec…
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider functional precision medicine approaches as potential complements to guideline-concordant care for non-metastatic colorectal cancer management.

This commentary addresses the management of patients with non-metastatic colorectal cancer, focusing on the limitations of current treatment paradigms and the potential utility of functional precision medicine approaches. The authors utilize hypothetical patient journeys and illustrative examples drawn from a retrospective cohort to explore these concepts. The text highlights that current practice often fails to align with patient needs despite being guideline-concordant, specifically regarding inter-patient and intra-tumoral heterogeneity that contributes to treatment resistance, recurrence, and unnecessary toxicity.

The discussion centers on functional precision medicine approaches, including genomic profiling and ex vivo drug responses, as potential tools to refine therapy selection and improve surveillance strategies. The commentary suggests that these methods can aid in the identification of intra-patient heterogeneity and differential drug sensitivity, thereby facilitating therapeutic stratification. However, the authors emphasize that guideline-concordant care remains necessary, even if it is not sufficient for all patients.

No specific adverse events, serious adverse events, discontinuations, or tolerability data were reported, as the study is a commentary rather than a clinical trial. Key limitations include the shortcomings of modern tools such as genomic profiling and the inherent constraints of current treatment paradigms. The authors caution that while functional precision medicine approaches have the potential to complement existing treatment paradigms, they are not definitive solutions. Continued research efforts are required to validate these technologies before they can be fully integrated into standard practice.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Colorectal cancer is a major healthcare burden, and modern management of non-metastatic disease largely depends on guideline-concordant care based on histopathologic staging and empiric systemic therapy. While multidisciplinary care pathways and standardized guidelines have improved outcomes at the population level, they fall short in addressing the inter-patient and intra-tumoral heterogeneity that contributes to treatment resistance, recurrence of the disease, and unnecessary toxicity. Using a hypothetical patient journey, this commentary highlights how current practice often fails to align with patient needs despite being guideline-concordant. We discuss the limitations of current treatment paradigms and the shortcomings of modern tools such as genomic profiling, highlighting the continued need for complementary approaches. We hypothesize that functional precision medicine approaches have the potential to complement existing treatment paradigms and improve therapeutic stratification. We provide illustrative examples of their potential utility drawn from our recent clinical correlation study on colorectal cancer, in which we reported an association between assay outcomes and clinical response in a retrospective cohort. Additionally, we demonstrate the ability to identify intra-patient heterogeneity in ex vivo drug responses, suggesting phenotypically distinct subpopulations with differential drug sensitivity. Further investigation leading to the integration of these or similar technologies alongside genomic and minimal residual disease assessments could refine therapy selection and improve existing surveillance strategies. Ultimately, we suggest that while guideline-concordant care remains necessary, it is not sufficient for all patients. Continued research efforts utilizing functional precision medicine technologies may enable colorectal cancer management to move toward a more personalized framework that maximizes patient outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.